{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T20:58:30Z","timestamp":1794603510186,"version":"4.9.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1038\/s41591-025-03783-8","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T09:02:43Z","timestamp":1752656563000},"page":"3028-3036","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["CLDN18.2\u2013targeting antibody\u2013drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4442-6516","authenticated-orcid":false,"given":"Jia","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3798-7024","authenticated-orcid":false,"given":"Jifang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4914-6508","authenticated-orcid":false,"given":"Meili","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongfeng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuying","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Tazbirkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zimin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanru","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieer","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6697-7143","authenticated-orcid":false,"given":"Xianjun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuangxin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enxiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianglin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0246-0786","authenticated-orcid":false,"given":"Michelle","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingmei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8798-4756","authenticated-orcid":false,"given":"Lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"3783_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"3783_CR2","doi-asserted-by":"publisher","first-page":"110074","DOI":"10.1016\/j.isci.2024.110074","volume":"27","author":"F Zhao","year":"2024","unstructured":"Zhao, F., Yang, D., Lan, Y. & Li, X. Different trends of gastric cancer in China, Japan, Republic of Korea and United States of America. iScience 27, 110074 (2024).","journal-title":"iScience"},{"key":"3783_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41575-022-00726-3","volume":"20","author":"J Huang","year":"2023","unstructured":"Huang, J. et al. Updated epidemiology of gastrointestinal cancers in East Asia. Nat. Rev. Gastroenterol. Hepatol. 20, 271\u2013287 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"3783_CR4","first-page":"47","volume":"4","author":"B Han","year":"2024","unstructured":"Han, B. et al. Cancer incidence and mortality in China, 2022. J. Natl Cancer Cent. 4, 47\u201353 (2024).","journal-title":"J. Natl Cancer Cent."},{"key":"3783_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398, 27\u201340 (2021).","journal-title":"Lancet"},{"key":"3783_CR6","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha, S. Y. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 24, 1181\u20131195 (2023).","journal-title":"Lancet Oncol."},{"key":"3783_CR7","doi-asserted-by":"publisher","first-page":"e078876","DOI":"10.1136\/bmj-2023-078876","volume":"385","author":"M-Z Qiu","year":"2024","unstructured":"Qiu, M.-Z. et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ 385, e078876 (2024).","journal-title":"BMJ"},{"key":"3783_CR8","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke, H. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 15, 1224\u20131235 (2014).","journal-title":"Lancet Oncol."},{"key":"3783_CR9","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41571-024-00874-2","volume":"21","author":"I Nakayama","year":"2024","unstructured":"Nakayama, I. et al. Claudin 18.2 as a novel therapeutic target. Nat. Rev. Clin. Oncol. 21, 354\u2013369 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"3783_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1132319","volume":"13","author":"J Chen","year":"2023","unstructured":"Chen, J. et al. Targeting CLDN18.2 in cancers of the gastrointestinal tract: new drugs and new indications. Front. Oncol. 13, 1132319 (2023).","journal-title":"Front. Oncol."},{"key":"3783_CR11","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s40265-024-02056-x","volume":"84","author":"SJ Keam","year":"2024","unstructured":"Keam, S. J. Zolbetuximab: first approval. Drugs 84, 977\u2013983 (2024).","journal-title":"Drugs"},{"key":"3783_CR12","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/d41573-024-00172-7","volume":"23","author":"A Mullard","year":"2024","unstructured":"Mullard, A. FDA approves first claudin-18.2-targeted antibody for gastric cancer. Nat. Rev. Drug Discov. 23, 884 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3783_CR13","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah, M. A. et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat. Med. 29, 2133\u20132141 (2023).","journal-title":"Nat. Med."},{"key":"3783_CR14","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara, K. et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 401, 1655\u20131668 (2023).","journal-title":"Lancet"},{"key":"3783_CR15","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1056\/NEJMc2409512","volume":"391","author":"K Shitara","year":"2024","unstructured":"Shitara, K. et al. Zolbetuximab in gastric or gastroesophageal junction adenocarcinoma. N. Engl. J. Med. 391, 1159\u20131162 (2024).","journal-title":"N. Engl. J. Med."},{"key":"3783_CR16","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1200\/JCO.2024.42.16_suppl.4011","volume":"42","author":"J Hao","year":"2024","unstructured":"Hao, J. et al. Safety and efficacy of IBI389, an anti-CLDN18.2\/CD3 bispecific antibody, in patients with advanced pancreatic ductal adenocarcinoma: preliminary results from a phase 1 study. J. Clin. Oncol. 42, 4011 (2024).","journal-title":"J. Clin. Oncol."},{"key":"3783_CR17","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1200\/JCO.2024.42.16_suppl.2519","volume":"42","author":"L Zheng","year":"2024","unstructured":"Zheng, L. et al. Safety and preliminary efficacy results of IBI389, an anti-CLDN18.2\/CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study. J. Clin. Oncol. 42, 2519 (2024).","journal-title":"J. Clin. Oncol."},{"key":"3783_CR18","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat. Med. 28, 1189\u20131198 (2022).","journal-title":"Nat. Med."},{"key":"3783_CR19","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","volume":"30","author":"C Qi","year":"2024","unstructured":"Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Nat. Med. 30, 2224\u20132234 (2024).","journal-title":"Nat. Med."},{"key":"3783_CR20","doi-asserted-by":"publisher","first-page":"434420","DOI":"10.1200\/JCO.2023.41.36_suppl.434420","volume":"41","author":"R-H Xu","year":"2023","unstructured":"Xu, R.-H. et al. A phase 1 trial of claudin 18.2-specific antibody-drug conjugate CMG901 in patients with advanced gastric\/gastroesophageal junction cancer. J. Clin. Oncol. 41, 434420 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3783_CR21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu, Z., Li, S., Han, S., Shi, C. & Zhang, Y. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Signal Transduct. Target. Ther. 7, 93 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"3783_CR22","doi-asserted-by":"publisher","first-page":"LB057","DOI":"10.1158\/1538-7445.AM2024-LB057","volume":"84","author":"S Zhou","year":"2024","unstructured":"Zhou, S. et al. Abstract LB057: pre-clinical characterization of IBI343, a site-specifically conjugated anti-Claundin18.2 ADC, for treating solid tumors. Cancer Res. 84, LB057 (2024).","journal-title":"Cancer Res."},{"key":"3783_CR23","doi-asserted-by":"publisher","first-page":"S160","DOI":"10.1016\/j.annonc.2024.05.311","volume":"35","author":"JJ Liu","year":"2024","unstructured":"Liu, J. J. et al. 396MO Anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with solid tumors and gastric\/gastro-esophageal junction adenocarcinoma (G\/GEJ AC): a phase I study. Ann. Oncol. 35, S160 (2024).","journal-title":"Ann. Oncol."},{"key":"3783_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2023.100284","volume":"104","author":"B Jasani","year":"2024","unstructured":"Jasani, B. et al. Global ring study to investigate the comparability of total assay performance of commercial Claudin 18 antibodies for evaluation in gastric cancer. Lab. Invest. 104, 100284 (2024).","journal-title":"Lab. Invest."},{"key":"3783_CR25","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/bdd.2371","volume":"44","author":"H Habara","year":"2023","unstructured":"Habara, H. et al. Transition of average drug-to-antibody ratio of trastuzumab deruxtecan in systemic circulation in monkeys using a hybrid affinity capture liquid chromatography-tandem mass spectrometry. Biopharm. Drug Dispos. 44, 380\u2013384 (2023).","journal-title":"Biopharm. Drug Dispos."},{"key":"3783_CR26","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1093\/annonc\/mdz199","volume":"30","author":"O T\u00fcreci","year":"2019","unstructured":"T\u00fcreci, O. et al. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann. Oncol. 30, 1487\u20131495 (2019).","journal-title":"Ann. Oncol."},{"key":"3783_CR27","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S1470-2045(24)00636-3","volume":"26","author":"D-Y Ruan","year":"2025","unstructured":"Ruan, D.-Y. et al. Claudin 18.2-targeting antibody\u2013drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial. Lancet Oncol. 26, 227\u2013238 (2025).","journal-title":"Lancet Oncol."},{"key":"3783_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1517\/14740338.4.1.45","volume":"4","author":"K Seiter","year":"2005","unstructured":"Seiter, K. Toxicity of the topoisomerase I inhibitors. Expert Opin. Drug Saf. 4, 45\u201353 (2005).","journal-title":"Expert Opin. Drug Saf."},{"key":"3783_CR29","doi-asserted-by":"crossref","unstructured":"Rowinsky, E. K. in Camptothecins in Cancer Therapy (eds Adams, V. R. & Burke, T. G.) 317\u2013341 (Humana, 2005).","DOI":"10.1385\/1-59259-866-8:317"},{"key":"3783_CR30","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","volume":"19","author":"K Shitara","year":"2018","unstructured":"Shitara, K. et al. Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 19, 1437\u20131448 (2018).","journal-title":"Lancet Oncol."},{"key":"3783_CR31","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"Y-K Kang","year":"2017","unstructured":"Kang, Y.-K. et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 2461\u20132471 (2017).","journal-title":"Lancet"},{"key":"3783_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejca.2018.05.007","volume":"100","author":"U Sahin","year":"2018","unstructured":"Sahin, U. et al. A phase I dose-escalation study of IMAB362 (zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer. Eur. J. Cancer 100, 17\u201326 (2018).","journal-title":"Eur. J. Cancer"},{"key":"3783_CR33","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/s41591-024-02992-x","volume":"30","author":"K Shitara","year":"2024","unstructured":"Shitara, K. et al. Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial. Nat. Med. 30, 1933\u20131942 (2024).","journal-title":"Nat. Med."},{"key":"3783_CR34","doi-asserted-by":"publisher","first-page":"217362","DOI":"10.1016\/j.canlet.2024.217362","volume":"611","author":"A Tojjari","year":"2024","unstructured":"Tojjari, A., Idrissi, Y. A. & Saeed, A. Emerging targets in gastric and pancreatic cancer: focus on claudin 18.2. Cancer Lett. 611, 217362 (2024).","journal-title":"Cancer Lett."},{"key":"3783_CR35","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N. Engl. J. Med. 390, 875\u2013888 (2024).","journal-title":"N. Engl. J. Med."},{"key":"3783_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102395","volume":"106","author":"E Nicol\u00f2","year":"2022","unstructured":"Nicol\u00f2, E. et al. Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. Cancer Treat. Rev. 106, 102395 (2022).","journal-title":"Cancer Treat. Rev."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03783-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03783-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03783-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:09:55Z","timestamp":1788516595000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03783-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3783"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03783-8","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.L. declares honoraria from Merck Sharp & Dohme and Specialised Therapeutics, consulting or advisory roles for Starpharma and Greywolf Therapeutics, research funding from Starpharma, ViroCure, Corvus Pharmaceuticals, Relay Therapeutics, ALX Oncology, IDEAYA Biosciences, Innovent Biologics, Greywolf Therapeutics, Merck Sharp & Dohme, Regeneron, Bristol Myers Squibb, AbbVie and AVEO, and travel, accommodation and expenses from Starpharma, ImmVirX, Merck Sharp & Dohme and Innovent Biologics. Y.L., X.Z., Y.G. and H.Z. are employees of Innovent Biologics. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}